Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
Pharmaceutics · 28.12.2024 · 17 (1) · 32
DOI: 10.3390/pharmaceutics17010032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 28.12.2024. Verfasst von Yawen Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, National Center of Technology Innovation for Biopharmaceuticals.
Abstract (Originalsprache)
Objective
Liver fibrosis, a hallmark of chronic liver diseases, is characterized by excessive extracellular matrix (ECM) deposition and scar tissue formation. Current antifibrotic nanomedicines face significant limitations, including poor penetration into fibrotic tissue, rapid clearance, and suboptimal therapeutic efficacy. The dense fibrotic ECM acts as a major physiological barrier, necessitating the development of a targeted delivery strategy to achieve effective therapeutic outcomes.
Methods
We designed a liposomal delivery system functionalized with the GBI-10 aptamer and encapsulating obeticholic acid (OCA lips@Apt) to enhance selective delivery to fibrotic liver tissue while minimizing systemic toxicity.
Results
Both in vitro and in vivo studies demonstrated that the aptamer-modified OCA liposomes effectively treated hepatic fibrosis through dual mechanisms: modulation of abnormal bile acid metabolism and attenuation of inflammation. The targeted delivery system leveraged the overexpression of Tenascin-C (TnC), a key ECM component in fibrotic tissues, for precise localization and enhanced endocytosis via the exposed cationic liposome surface.
Conclusions
The OCA lips@Apt nanodrug demonstrated superior therapeutic efficacy with minimal off-target effects, offering a promising strategy to overcome critical barriers in liver fibrosis treatment. By precisely targeting the fibrotic ECM and modulating key pathological pathways, this TnC-guided liposomal delivery system provides a significant advancement in antifibrotic nanomedicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
- State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing 210009, China.
- NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Hongliang He, Lisha Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- National Center of Technology Innovation for Biopharmaceuticals
- Innovation and Entrepreneurship Training Program for Undergraduate in China Phar-maceutical University
- Innovation and Entrepreneurship Training Program for Undergraduate in China Pharmaceutical University
Zitieren
APA
Wang, Y., Yang, L., Xu, Q., Liu, T., He, H., Liu, L., & Yin, L. (2024). Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy. Pharmaceutics, 17(1), 32. https://doi.org/10.3390/pharmaceutics17010032
Vancouver
Wang Y, Yang L, Xu Q, Liu T, He H, Liu L, et al. Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy. Pharmaceutics. 2024;17(1):32. doi:10.3390/pharmaceutics17010032
BibTeX
@article{Wang2024,
author = {Wang, Yawen and Yang, Lei and Xu, Qing and Liu, Taiyu and He, Hongliang and Liu, Lisha and Yin, Lifang},
title = {Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy},
journal = {Pharmaceutics},
year = {2024},
volume = {17},
number = {1},
pages = {32},
doi = {10.3390/pharmaceutics17010032}
}
EUVIMED